Polyplex Formation via Microfluidic Mixing for Gene Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current gene delivery protocols using viral vectors face challenges such as immunogenic responses, transgene insertional mutagenesis, limited scalability, and low 'cargo capacity' for genetic materials, necessitating the development of more effective and safer non-viral gene vectors.

Innovation Solution

A method for preparing polyplexes by contacting a polymer in a first liquid stream with a nucleic acid component in a second liquid stream, under controlled conditions to form polyplexes with suitable size and charge for therapeutic administration, and then isolating and stabilizing these polyplexes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If viral vectors are used for gene delivery, then gene delivery efficiency is improved, but immunogenic responses and transgene insertional mutagenesis occur

Engineering Contradiction:

Improvegene delivery efficiencyVSAvoidimmunogenic responses and transgene insertional mutagenesis

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces persistent viral vectors with degradable polymer-based polyplexes that can be enzymatically broken down into harmless metabolites. The polymer structure is designed to be temporarily active for gene delivery then degraded, eliminating the long-term safety concerns associated with viral vectors and their ability to cause insertional mutagenesis or immunogenic responses.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent modifies the chemical and physical parameters of the gene delivery system by transitioning from viral vectors to synthetic polymers with controllable degradation rates. The polymer structure, molecular weight, and composition are adjusted to achieve optimal gene delivery while ensuring safety through controlled breakdown into non-harmful substances.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If viral vectors are used for gene delivery, then gene delivery capability is improved, but large-scale production is limited

Engineering Contradiction:

Improvegene delivery capabilityVSAvoidlarge-scale production

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent employs synthetic polymer components that can be manufactured at scale using established chemical synthesis methods, replacing viral vector production which requires complex cellular systems. The polymer-based polyplexes can be produced through standardized protocols and scaled independently of biological production constraints.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent replaces the biological production system (viral vectors requiring cell cultures and purification) with a chemical synthesis approach. This substitution enables more straightforward scaling from laboratory to industrial production, as chemical synthesis pathways are inherently more scalable than biological systems.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Productivity

If viral vectors are used for gene delivery, then gene expression is achieved, but cargo capacity for genetic materials is limited

Engineering Contradiction:

Improvegene expressionVSAvoidcargo capacity for genetic materials

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent adjusts the molecular weight, charge density, and structural parameters of the polymer to maximize cargo capacity. By optimizing these physical and chemical parameters, the polyplexes can accommodate larger amounts of genetic material while maintaining stability and cellular uptake, thereby increasing the payload capacity compared to viral vectors.

Inventive Principle:

Principle #35Parameter changes

4Productivity

If polyplexes are formed with tight control of physical parameters, then transfection efficiency is improved, but manufacturing complexity increases

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidmanufacturing process complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent establishes specific ranges for polymer molecular weight, charge density, and composition that optimize transfection efficiency. By defining these parameters within optimal ranges rather than requiring precise control, the process becomes more manufacturable while still achieving high transfection efficiency. The degradation rate and other parameters are controlled to be within practical manufacturing capabilities.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method enables the production of uniform and stable polyplexes with improved transfection efficiency and safety, facilitating the advancement of polymer-based gene therapies towards clinical applications.

Implementation Method 1

contacting the polymer in the first liquid stream with the nucleic acid component in the second liquid stream to form a polyplex having a size and charge that is suitable for therapeutic administration

Methodology Applied

Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentUS20250041458A1Methods for forming polyplexes

Publication Date: 2025.02.06 AMRYT GENETICS LTD

AI summary

The present disclosure relates method for forming polyplexes, which find use in gene therapy applications as safe and non-toxic nucleic acid transfection agents.